Your browser doesn't support javascript.
loading
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.
Tang, Rong; Zheng, Hui; Wang, Bu-Sen; Gou, Jin-Bo; Guo, Xi-Ling; Chen, Xiao-Qin; Chen, Yin; Wu, Shi-Po; Zhong, Jin; Pan, Hong-Xing; Zhu, Jia-Hong; Xu, Xiao-Yu; Shi, Feng-Juan; Li, Zhuo-Pei; Liu, Jing-Xian; Zhang, Xiao-Yin; Cui, Lun-Biao; Song, Zhi-Zhou; Hou, Li-Hua; Zhu, Feng-Cai; Li, Jing-Xin.
Afiliación
  • Tang R; NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu Province, China.
  • Zheng H; School of Public Health, Southeast University, Nanjing, Jiangsu Province, China.
  • Wang BS; Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China.
  • Gou JB; Tianjin CanSino Biotechnology, Tianjin, China.
  • Guo XL; NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu Province, China.
  • Chen XQ; Donghai County Center for Disease Control and Prevention, Donghai, Jiangsu Province, China.
  • Chen Y; NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu Province, China.
  • Wu SP; Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China.
  • Zhong J; Donghai County Center for Disease Control and Prevention, Donghai, Jiangsu Province, China.
  • Pan HX; NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu Province, China.
  • Zhu JH; Lianshui County Center for Disease Control and Prevention, Lianshui, Jiangsu Province, China.
  • Xu XY; Vazyme Biotech, Nanjing, Jiangsu Province, China.
  • Shi FJ; NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu Province, China.
  • Li ZP; School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, China.
  • Liu JX; NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu Province, China.
  • Zhang XY; School of Public Health, Southeast University, Nanjing, Jiangsu Province, China.
  • Cui LB; NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu Province, China.
  • Song ZZ; Lianshui County Center for Disease Control and Prevention, Lianshui, Jiangsu Province, China.
  • Hou LH; Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China. Electronic address: houlihua@sina.com.
  • Zhu FC; NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu Province, China; School of Public Health, Southeast University, Nanjing, Jiangsu Province, China; School of Public Health, Nanjing Medical University, Nanjing, Jiangs
  • Li JX; NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu Province, China; School of Public Health, Southeast University, Nanjing, Jiangsu Province, China; School of Public Health, Nanjing Medical University, Nanjing, Jiangs
Lancet Respir Med ; 11(7): 613-623, 2023 07.
Article en En | MEDLINE | ID: mdl-36898400
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Humans Idioma: En Revista: Lancet Respir Med Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Humans Idioma: En Revista: Lancet Respir Med Año: 2023 Tipo del documento: Article País de afiliación: China